Clinical Trial Update: Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV [Phase 3]

View source ↗

Summary

Phase 3 trial update on ibalizumab with optimized background regimen in patients with multi-drug resistant HIV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ibalizumab (ibalizumab)

Snippet

Sponsor: TaiMed Biologics Inc. | Conditions: HIV | Phase 3 | Status: COMPLETED | Results posted: 2020-03-19